Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;96(3):656-659.
doi: 10.4269/ajtmh.16-0811. Epub 2017 Apr 6.

Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis

Caroline R Espada  1 , Fatima Ribeiro-Dias  2 , Miriam L Dorta  2 , Ledice Inácia de Araújo Pereira  2 , Edgar M de Carvalho  3   4 , Paulo R Machado  4 , Albert Schriefer  4 , Jenicer K U Yokoyama-Yasunaka  1 , Adriano C Coelho  1   5 , Silvia R B Uliana  1
Affiliations

Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis

Caroline R Espada et al. Am J Trop Med Hyg. 2017 Mar.

Abstract

Leishmania (Viannia) braziliensis is the main causative species of tegumentary leishmaniasis in Brazil. In this study, we evaluated the susceptibility of 16 clinical isolates of L. (V.) braziliensis from different regions of Brazil to miltefosine in vitro. Half-maximal inhibitory concentrations of miltefosine varied from 22.9 to 144.2 μM against promastigotes and from 0.3 to 4.2 μM against intracellular amastigotes. No significant differences were found between isolates of different geographical origins. A clear correlation between the EC50 against promastigotes and amastigotes within each isolate was found. These findings contribute to the evaluation of miltefosine's potential and limitations for the treatment of tegumentary leishmaniasis in Brazil.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Susceptibility of promastigotes and intracellular amastigotes of Leishmania (V.) braziliensis isolates to miltefosine. (A) EC50 determined against promastigotes. (B) EC50 determined against intracellular amastigotes. “T” indicates the type strains M2903 and H3227, “GO” isolates from Goiás, and “BA” isolates from Bahia. (C) Comparison between the EC50 against promastigotes and amastigotes. The box indicates the 25th–75th percentiles. The line in the middle of the box indicates the median; * P < 0.0001 (Mann–Whitney test). (D) Correlation between the EC50 determined against promastigotes and amastigotes for each clinical isolate. Spearman coefficient r = 0.793; P = 0.008.
See this image and copyright information in PMC

References

    1. Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4:e912. - PMC - PubMed
    1. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739–1746. - PubMed
    1. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007;44:350–356. - PubMed
    1. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004;38:1266–1272. - PubMed
    1. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg. 2011;84:255–260. - PMC - PubMed

Publication types

LinkOut - more resources